reviewTop 1% cited
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Nature reviews. Cancer · 2009 · Vol. 9(8) · pp. 550–562
Jeffrey A. Engelman✉(Harvard University)
PI3K/AKT/mTOR signaling in cancerCancer Mechanisms and TherapyLung Cancer Treatments and MutationsPI3K/AKT/mTOR pathwaySignalling pathwaysCancerProtein kinase BPaceMedicineSignallingPTENCancer treatmentCancer research
MeSH terms
Antineoplastic AgentsHumansNeoplasmsProtein KinasesSignal TransductionPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases
Funding
- National Institutes of Health
Citations
2,438
FWCI
68.71
field-weighted impact
References
160
Percentile
100%
vs. same field & year
Citations per year
Cited by
Targeting RTK Signaling Pathways in Cancer
Cancers · 2015 · 375 citations
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Oncotarget · 2016 · 533 citations
FOXO Transcription Factors: Their Clinical Significance and Regulation
BioMed Research International · 2014 · 418 citations
PI3K and cancer: lessons, challenges and opportunities
Nature Reviews Drug Discovery · 2014 · 1,716 citations
The molecular biology of head and neck cancer
Nature reviews. Cancer · 2010 · 2,533 citations
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
The Journal of Pathology · 2009 · 483 citations
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
European Journal of Medicinal Chemistry · 2016 · 607 citations
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Cancer Cell · 2012 · 1,350 citations
References
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Biochemical Journal · 2008 · 1,234 citations
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Nature Reviews Genetics · 2006 · 3,288 citations
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Nature Cell Biology · 2002 · 3,038 citations
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
Cancer Cell · 2007 · 1,609 citations
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
PLoS Biology · 2009 · 1,072 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Genes & Development · 2003 · 1,900 citations
Molecular alterations of the <i>AKT</i>2 oncogene in ovarian and breast carcinomas
International Journal of Cancer · 1995 · 836 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.